INSIGHTS ON CLINICAL TRIAL PARTNERING

• Navigating Autoimmune Disease A Playbook For Cell And Gene Therapies

  By integrating site readiness, patient engagement, and data-driven decision-making, the cell and gene therapies (CAGT) field is advancing toward therapies that not only control disease but transform lives.

• 5 Myths About Patient Payments In Clinical Trials

  Digital payment solutions debunk myths around clinical trial compensation, improving participant retention, easing site burden, and enabling smoother global operations through faster, more reliable payments.

• Consolidating Access Into A Single Platform: A Site CEO's Perspective

  By providing research sites with a unified, streamlined interface, we can reduce operational friction, enhance collaboration, and ultimately accelerate the development of new therapies.

• Clinical Trial Payments And Ethics: Your Top Questions Answered

  Fair compensation in trials requires distinguishing reimbursement from stipends. Learn the ethical principles that ensure payments uphold participant respect and remove financial barriers.

• Development And Manufacture Of A Highly Potent OSD Product

  10/20/2025

  Highly potent drug compounds require advanced containment and robust technical transfer protocols. CDMOs overcome challenges through meticulous testing, specialized tooling, and strong supplier relationships.

• Managing Medical Coding Dictionary Updates In Clinical Trials

  7/15/2026

  Dictionary updates can impact data consistency, safety monitoring, and reporting. Learn key considerations for managing coding version changes while maintaining data integrity.

• Specialized Site Network For Early-Phase Oncology Success

  10/2/2025

  Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

• The Lasting Impact Of Treatment Gaps In ARG1-D

  6/26/2026

  A patient story from ARG1-D reveals how even brief treatment interruptions can trigger irreversible decline and why continuity of care must remain a priority in rare disease research.

• Strategic Considerations For Oncology Trials In A Competitive Landscape

  5/14/2025

  By combining strategic foresight with hands-on support, the right partner accelerates oncology trial delivery and broadens access to promising therapies.